Resource impact statement
No resource impact is anticipated
No resource impact is anticipated from this technology appraisal. Degarelix is another treatment option for advanced hormone-dependent prostate cancer in people with spinal metastases. Because of the small number of people who may have treatment, it is considered that clinical practice will not change substantially as a result of this guidance.
A benefit of degarelix is that there is no testosterone flare at the start of treatment. This avoids the cost of using an anti-androgen treatment to prevent flares.
Degarelix is commissioned by clinical commissioning groups. Providers are NHS hospital trusts and primary care GP services.
This page was last updated: 24 August 2016